March 15, 2015

New Drug Approved for Children with High-Risk Neuroblastoma

On March 10, 2015, the FDA approved dinutuximab (ch14.18, Unituxin) as part of treatment for children with high-risk neuroblastoma. The approval was based on the results of two major Children’s Oncology Group (COG) research trials and culminates a remarkable collaborative research effort that spanned more than two decades of research. The new drug is an antibody directed against a protein that is found on neuroblastoma cells. The antibody can be used in addition to other forms of treatment (chemotherapy, radiation therapy and surgery) for children with high-risk neuroblastoma.

This advance would not have been possible were it not for the willingness of the children we care for and their families to participate in the Children’s Oncology Group’s research efforts. We are thus grateful to the many children and families who helped make this advance possible. Although FDA approval of a first in children new treatment is an important step forward, we recognize that even with the addition of dinutuximab to our treatment efforts, we still have a long road ahead to improve the outcome and quality of life for children with neuroblastoma and other childhood cancers.

Peter C. Adamson, MD

Chair, Children’s Oncology Group

© The Children's Oncology Group
The information and content provided on this website is made available for informational purposes only for children and their families affected by cancer. While the Children's Oncology Group strives to provide accurate and up-to-date information, the information may be out of date or incomplete in certain respects. Please do not rely on this information and seek the care of a qualified medical professional if you have questions regarding a specific medical condition, disease, diagnosis or symptom. The information and content presented herein is not intended to replace the independent clinical judgement, medical advice, screening, health counseling, or other intervention performed by your (or your child's) health care provider. Please contact "911" or your emergency services if this is a health emergency. No endorsement of any specific tests, products, or procedures is made herein.